Who are KI1001's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Platelet Rich Plasma (PRP), ACP, Autologous platelets rich plasma, Low-dose PRP, Leukocyte rich platelet rich plasma, Cellular Matrix / A-CP-HA Kit.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ki1001.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

KI1001 — Competitive Intelligence Brief

KI1001 (KI1001) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy / Regenerative medicine. Area: Ophthalmology.

phase 3 Cell therapy / Regenerative medicine Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

KI1001 (KI1001) — Kuhnil Pharmaceutical Co., Ltd.. KI1001 is a regenerative medicine therapy designed to restore corneal endothelial cell function and transparency in corneal diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
KI1001 TARGET	KI1001	Kuhnil Pharmaceutical Co., Ltd.	phase 3	Cell therapy / Regenerative medicine
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
ACP	ACP	Istituto Ortopedico Rizzoli	marketed	Cell therapy / Regenerative medicine product
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product
Low-dose PRP	Low-dose PRP	Hospital for Special Surgery, New York	marketed	Autologous cell therapy / Regenerative medicine product
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
Cellular Matrix / A-CP-HA Kit	Cellular Matrix / A-CP-HA Kit	Fundación Santiago Dexeus Font	marketed	Cell therapy / Regenerative medicine product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy / Regenerative medicine class)

American University of Beirut Medical Center · 1 drug in this class
Kuhnil Pharmaceutical Co., Ltd. · 1 drug in this class
Stemform · 1 drug in this class
Taejoon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KI1001 — Competitive Intelligence Brief. https://druglandscape.com/ci/ki1001. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab